×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NTLA – intellia therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NTLA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/12
05:26 am
ntla
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares [Yahoo! Finance]
High
Report
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares [Yahoo! Finance]
1/10
07:02 pm
ntla
Fred Cohen Buys 303% More Intellia Therapeutics Shares [Yahoo! Finance]
High
Report
Fred Cohen Buys 303% More Intellia Therapeutics Shares [Yahoo! Finance]
1/7
07:12 pm
ntla
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/7
07:30 am
ntla
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/5
01:03 pm
ntla
Intellia Stock Declines Around 55% in 3 Months: Here's Why [Yahoo! Finance]
Low
Report
Intellia Stock Declines Around 55% in 3 Months: Here's Why [Yahoo! Finance]
1/3
10:01 am
ntla
We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully [Yahoo! Finance]
Low
Report
We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully [Yahoo! Finance]
1/2
04:01 pm
ntla
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/31
06:32 am
ntla
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab [Yahoo! Finance]
Low
Report
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
04:00 pm
ntla
intellia therapeutics, inc.
BEAT
Report
-22.7%
intellia therapeutics, inc.
8/7/2025
07:30 am
ntla
intellia therapeutics, inc.
BEAT
Report
-1.7%
intellia therapeutics, inc.
5/8/2025
07:30 am
ntla
intellia therapeutics, inc.
BEAT
Report
9.5%
intellia therapeutics, inc.
2/27/2025
07:30 am
ntla
intellia therapeutics, inc.
BEAT
Report
-4.7%
intellia therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/9
08:07 am
ntla
Form 8-K Intellia Therapeutics, For: Jan 09
Low
Report
Form 8-K Intellia Therapeutics, For: Jan 09
1/7
04:06 pm
ntla
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: LEONARD JOHN M
Low
Report
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: LEONARD JOHN M
1/7
04:05 pm
ntla
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: Lebwohl David
Medium
Report
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: Lebwohl David
1/7
04:05 pm
ntla
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: Schultes Birgit C
Low
Report
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: Schultes Birgit C
1/7
04:05 pm
ntla
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: BASTA JAMES
Low
Report
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: BASTA JAMES
1/7
04:05 pm
ntla
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: Cohen Fred E
Low
Report
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: Cohen Fred E
1/7
04:04 pm
ntla
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: Clark Eliana
Medium
Report
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: Clark Eliana
1/7
04:03 pm
ntla
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: Dulac Edward J III
Medium
Report
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: Dulac Edward J III
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/27
Intellia Therapeutics, Inc. (NTLA) Q4 2019 Earnings Call Transcript [The Motley Fool]
17.1%
10/31 Intellia Therapeutics, Inc. (NTLA) Q3 2019 Earnings Call Transcript [The Motley Fool] 9.0%
2/10 Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference 7.6%
11/23 More CRISPR Stock Catalysts Ahead [The Motley Fool] 6.3%
4/22 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.3%
6/7 Form EFFECT Intellia Therapeutics, 5.6%
2/5 Here's Why CRISPR Stocks Fell in January [The Motley Fool] 5.0%
10/31 Q3/2019 9/30/2019 EPS -0.490 ZacksConsensus -0.610 ActVsEst 0.120 - Beat 5.0%
3/26 Form 8-K Intellia Therapeutics, For: Mar 26 4.2%
7/8 Intellia +1% after Baird start at Outperform [Seeking Alpha] 4.2%
10/31 Intellia Therapeutics, Inc. (NTLA) Q3 2019 Earnings Call Transcript [The Motley Fool] 9.0%
2/10 Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference 7.6%
11/23 More CRISPR Stock Catalysts Ahead [The Motley Fool] 6.3%
4/22 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.3%
6/7 Form EFFECT Intellia Therapeutics, 5.6%
2/5 Here's Why CRISPR Stocks Fell in January [The Motley Fool] 5.0%
10/31 Q3/2019 9/30/2019 EPS -0.490 ZacksConsensus -0.610 ActVsEst 0.120 - Beat 5.0%
3/26 Form 8-K Intellia Therapeutics, For: Mar 26 4.2%
7/8 Intellia +1% after Baird start at Outperform [Seeking Alpha] 4.2%
TOP News Decliners
3/13
Form 8-K Intellia Therapeutics, For: Mar 12
-17.6%
6/10 Intellia Therapeutics Inc (NASDAQ: NTLA) is now covered by analysts at Roth Capital. They set a "neutral" rating and a $16.00 price target on the stock. -10.3%
4/1 Intellia Therapeutics Inc (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $57.50 price target on the stock. -8.8%
8/26 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -8.2%
4/28 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. -7.8%
9/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was given a new $57.50 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. -7.7%
5/7 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
4/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.6%
4/21 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -7.5%
2/14 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. -7.3%
6/10 Intellia Therapeutics Inc (NASDAQ: NTLA) is now covered by analysts at Roth Capital. They set a "neutral" rating and a $16.00 price target on the stock. -10.3%
4/1 Intellia Therapeutics Inc (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $57.50 price target on the stock. -8.8%
8/26 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -8.2%
4/28 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. -7.8%
9/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was given a new $57.50 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. -7.7%
5/7 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
4/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.6%
4/21 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -7.5%
2/14 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. -7.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: